SOLGAR CO., INC. – Trademark Portfolio

Entity Type: 03

SOLGAR CO., INC. holds 20 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 19 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 2 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include VM-75, HY-BIO, SOLGAR, and VM-2000. The owner is based in NEW YORK, NY.

92 E. 10TH ST.

NEW YORK, NY 10003

20 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

SOLGAR CO., INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (19 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

3
Cosmetics & Cleaning (1 filing)

Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring

Frequently Asked Questions

How many trademarks does SOLGAR CO., INC. have?

SOLGAR CO., INC. has 20 U.S. trademarks filed with the USPTO. Of these, 6 registered, 1 abandoned, 13 cancelled.

What trademark classes does SOLGAR CO., INC. file in?

SOLGAR CO., INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are SOLGAR CO., INC.'s most well-known trademarks?

SOLGAR CO., INC.'s registered trademark portfolio includes well-known marks such as VM-75, HY-BIO, SOLGAR, and VM-2000. These are among 6 currently registered trademarks in the portfolio.

What is SOLGAR CO., INC.'s trademark registration success rate?

SOLGAR CO., INC. has a 30% trademark registration rate, with 6 out of 20 resolved applications resulting in successful registration. Currently, 0 applications are pending review.